Hikma Pharmaceuticals (Germany) Today
| HIK Stock | EUR 148.00 1.00 0.67% |
Performance8 of 100
| Odds Of DistressLess than 9
|
Hikma Pharmaceuticals is trading at 148.00 as of the 23rd of April 2024. This is a -0.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 148.0. Hikma Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Hikma Pharmaceuticals PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of May 2022 and ending today, the 23rd of April 2024. Click here to learn more.
Hikari Tsushin, Inc. sells office automation equipment in Japan. The company was founded in 1988 and is headquartered in Tokyo, Japan. HIKARI TSUSHIN is traded on Frankfurt Stock Exchange in Germany. The company has 44.31 M outstanding shares. More on Hikma Pharmaceuticals PLC
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Hikma Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hikma Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hikma Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President and CEO, USA | Michael Raya |
| Business Concentration | Telecom Services, Communication Services (View all Sectors) |
Hikma Pharmaceuticals PLC (HIK) is traded on Frankfurt Exchange in Germany and employs 5,310 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.03 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hikma Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Hikma Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hikma Pharmaceuticals PLC classifies itself under Communication Services sector and is part of Telecom Services industry. The entity has 44.31 M outstanding shares.
Hikma Pharmaceuticals PLC has accumulated about 1.81 B in cash with 51.03 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 39.34.
Check Hikma Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationHikma Pharmaceuticals secures a total of 44.31 Million outstanding shares. Hikma Pharmaceuticals secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Hikma Ownership Details
Hikma Stock Price Odds Analysis
In reference to a normal probability distribution, the odds of Hikma Pharmaceuticals jumping above the current price in 90 days from now is about 60.23%. The Hikma Pharmaceuticals PLC probability density function shows the probability of Hikma Pharmaceuticals stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Hikma Pharmaceuticals PLC has a beta of -18.7813. This usually indicates as returns on its benchmark rise, returns on holding Hikma Pharmaceuticals PLC are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Hikma Pharmaceuticals is expected to outperform its benchmark. In addition to that, hikma Pharmaceuticals PLC has an alpha of 8.3154, implying that it can generate a 8.32 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Hikma Pharmaceuticals to move above the current price in 90 days from now is about 60.23 (This Hikma Pharmaceuticals PLC probability density function shows the probability of Hikma Stock to fall within a particular range of prices over 90 days) .
Hikma Pharmaceuticals PLC Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Hikma Pharmaceuticals market risk premium is the additional return an investor will receive from holding Hikma Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Hikma Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Hikma Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Hikma Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 16.18 | |||
| Semi Deviation | 10.35 | |||
| Standard Deviation | 67.55 | |||
| Variance | 4563.36 |
Hikma Stock Against Markets
Picking the right benchmark for Hikma Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Hikma Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Hikma Pharmaceuticals is critical whether you are bullish or bearish towards Hikma Pharmaceuticals PLC at a given time. Please also check how Hikma Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hikma Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Hikma Pharmaceuticals Corporate Directors
Hikma Pharmaceuticals corporate directors refer to members of a Hikma Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Hikma Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Hikma Pharmaceuticals' board members must vote for the resolution. The Hikma Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Pamela Kirby | Non-Executive Independent Director | Profile | |
| John Castellani | Non-Executive Independent Director | Profile | |
| Ali AlHusry | Non-Executive Director | Profile | |
| Jochen Gann | Non-Executive Director | Profile |
How to buy Hikma Stock?
Before investing in Hikma Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Hikma Pharmaceuticals. To buy Hikma Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Hikma Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Hikma Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Hikma Pharmaceuticals PLC stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Hikma Pharmaceuticals PLC stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Hikma Pharmaceuticals PLC, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Hikma Pharmaceuticals PLC?
The danger of trading Hikma Pharmaceuticals PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Hikma Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Hikma Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Hikma Pharmaceuticals PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Hikma Stock analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |